CA2383737A1 - Muc-1 derived peptides - Google Patents
Muc-1 derived peptides Download PDFInfo
- Publication number
- CA2383737A1 CA2383737A1 CA002383737A CA2383737A CA2383737A1 CA 2383737 A1 CA2383737 A1 CA 2383737A1 CA 002383737 A CA002383737 A CA 002383737A CA 2383737 A CA2383737 A CA 2383737A CA 2383737 A1 CA2383737 A1 CA 2383737A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- cell
- seq
- analogue
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 43
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 42
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract 38
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims 17
- 210000001744 T-lymphocyte Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 108091033319 polynucleotide Proteins 0.000 claims 13
- 239000002157 polynucleotide Substances 0.000 claims 13
- 102000040430 polynucleotide Human genes 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 11
- 102000043129 MHC class I family Human genes 0.000 claims 10
- 108091054437 MHC class I family Proteins 0.000 claims 10
- 108091008874 T cell receptors Proteins 0.000 claims 10
- 239000013598 vector Substances 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 7
- 108090000288 Glycoproteins Proteins 0.000 claims 6
- 102000003886 Glycoproteins Human genes 0.000 claims 6
- 230000005867 T cell response Effects 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229960005486 vaccine Drugs 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010036972 HLA-A11 Antigen Proteins 0.000 claims 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000005859 cell recognition Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 210000005253 yeast cell Anatomy 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 abstract 2
- 108010008707 Mucin-1 Proteins 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Described are peptides and polypeptides derived from the MUC-1 polypeptide which are able to activate Cytotoxic T Lymphocyte (CTL) response, analogues of such peptides and polypeptides nucleotide sequences encoding such peptides a nd polypeptides and therapeutic uses thereof. Moreover, indications for selecti ng appropriate minimal antigenic MUC-1 polypeptides with reference to the HLA- type of the patient to be treated or tested are described.
Claims (37)
1. A polypeptide consisting of or comprising at least one amino acid sequence of at most 20 consecutive amino-acids defined in SEQ ID NO: 1, said polypeptide binding at least one MHC-I glycoprotein, with the proviso that said polypeptide is different from SEQ
ID NO: 2.
ID NO: 2.
2. The polypeptide of claim 1, wherein the amino acid sequence is selected from the group consisting of the amino acid sequences shown in SEQ ID NO: 3 to SEQ ID NO: 33, SEQ ID NO: 65 and SEQ ID NO: 66.
3. The polypeptide of claim 1 or 2, wherein the amino acid sequence is selected from the group consisting of:
(a) SEQ ID NO: 3 to SEQ ID NO: 6 and SEQ ID NO: 65 and SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoproteins of MHC-I;
(b) SEQ ID NO: 7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoproteins of MHC-I;
(c) SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
(d) SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoproteins of MHC-I;
(e) SEQ ID NO: 22 to SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoproteins of MHC-I;
(f) SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoproteins of MHC-I; and (g) SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoproteins of MHC-I.
(a) SEQ ID NO: 3 to SEQ ID NO: 6 and SEQ ID NO: 65 and SEQ ID NO: 66, and said polypeptide binds the HLA A2 glycoproteins of MHC-I;
(b) SEQ ID NO: 7 to SEQ ID NO: 15, and said polypeptide binds the HLA B7 glycoproteins of MHC-I;
(c) SEQ ID NO: 16 to SEQ ID NO: 19, and said polypeptide binds the HLA A3 glycoprotein of MHC-I;
(d) SEQ ID NO: 19 to SEQ ID NO: 21, and said polypeptide binds the HLA A11 glycoproteins of MHC-I;
(e) SEQ ID NO: 22 to SEQ ID NO: 25, and said polypeptide binds the HLA A24 glycoproteins of MHC-I;
(f) SEQ ID NO: 26 to SEQ ID NO: 29, and said polypeptide binds the HLA A1 glycoproteins of MHC-I; and (g) SEQ ID NO: 30 to SEQ ID NO: 33, and said polypeptide binds the HLA B8 glycoproteins of MHC-I.
4. An analogue of the polypeptide of any one of claims 1 to 3, which is capable of inhibiting the binding of the polypeptide or of an epitope contained in said polypeptide to a T cell receptor either by directly binding to the same T cell receptor or by binding to the same T cell receptor after being processed.
5. A polynucleotide encoding the polypeptide of any one of claims 1 to 3.
6. The polynucleotide of claim 5, comprising a nucleotide sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO: 64, and their complementary sequences.
7. A polynucleotide encoding the analogue of claim 4.
8. The polynucleotide of any one of claims 5 to 7, further containing elements allowing the expression of the polypeptide or analogue in a host cell.
9. The polynucleotide of claim 8, wherein said element for expression in a host cell is a promoter.
10. The polynucleotide of any one of claims 5 to 9, wherein said polynucleotide is associated with one or more compounds selected from the group consisting of transfecting agents, stabilizing agents and targeting agents.
11. A vector comprising at least one polynucleotide of any one of claims 5 to 10.
12. The vector of claim 11 comprising at least two different nucleotide sequences encoding at least two polypeptides as defined in claim 3.
13. The vector of claim 11 or 12 which is a plasmid.
14. The vector of claim 11 or 12, which is a viral vector.
15. A host cell comprising a polynucleotide of any one of claims 5 to 10 or a vector of any one of claims 11 to 14.
16. The host cell of claim 15, which is a prokaryotic cell, a yeast cell, or an animal cell, such as a mammalian cell.
17. A composition comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14, or a host cell of claim 15 or 16 or a combination of two or more of these different compounds.
18. The composition of claim 17, further comprising a pharmaceutical carrier.
19. Use of a polypeptide of any one of claims 1 to 3, of an analogue of claim 4, of a polynucleotide of any one of claims 5 to 10, of a vector of any one of claims 11 to 14, of a host cell of claim 15 or 16 or of a composition of claim 17 for the preparation of a medicament for effecting a CTL response in a subject.
20. A diagnostic composition comprising a polypeptide of any one of claims 1 to 3.
21. A vaccine comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a vector of any one of claims 11 to 14 or a host cell of claim 15 or 16, which vaccine is capable of stimulating a MHC class I restricted T cell response directed to an epitope as contained in a polypeptide of any one of claims 1 to 3.
22. The vaccine of claim 21 which comprises an adjuvant or a delivery system, which adjuvant or delivery system stimulates a MHC class I restricted response.
23. A T cell receptor which recognizes an epitope contained in a polypeptide of any one of claims 1 to 3 or a fragment of said T cell receptor which can recognize the epitope.
24. A T cell comprising the T cell receptor of claim 23.
25. The T cell of claim 24, which has been produced by replication in vitro.
26. A product that selectively binds a T cell receptor of claim 23.
27. The product of claim 26 which product comprises (a) an HLA molecule, or a fragment thereof, comprising a polypeptide of any one of claims 1 to 3 or an analogue of claim 4 in its peptide binding groove, or (b) an analogue of (a) which is capable of inhibiting the binding of (a) to a T cell receptor of claim 23.
28. A method of identifying a product of claim 26 or 27 comprising contacting a candidate substance with a T cell receptor or fragment of claim 23 and determining whether the candidate substance binds to the T cell receptor or fragment, the binding of the candidate substance to the T cell receptor or fragment indicating that the candidate substance is such a product.
29. A cell comprising a product of claim 26 or 27.
30. A method of identifying a MHC class I restricted T cell response, said method comprising contacting a population of cells comprising MHC class I restricted T cells with:
the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions suitable for the presentation of the polypeptide or analogue to the T cells, or a product of claim 26 or 27 or cells of claim 29; and determining whether the CD8 T cells recognize the polypeptide, analogue, the product or the cell, recognition by the T cells indicating the presence of a MHC class I
restricted T cell response.
the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions suitable for the presentation of the polypeptide or analogue to the T cells, or a product of claim 26 or 27 or cells of claim 29; and determining whether the CD8 T cells recognize the polypeptide, analogue, the product or the cell, recognition by the T cells indicating the presence of a MHC class I
restricted T cell response.
31. The method of claim 30, in which the determination of the T cell recognition is done by detecting the expression of a substance by the T cells, the expression of the substance indicating that the T cells have recognized the polypeptide, the analogue, the product or the cell.
32. The method of claim 31, in which the substance which is detected is IFN-.gamma..
33. A method of diagnosing cancer in a host said method comprising determining the presence or absence in the host of a MHC class I restricted T cell response to a polypeptide of any one of claims 1 to 3, the presence of the MHC class I
restricted T
cell response indicating that the host has cancer.
restricted T
cell response indicating that the host has cancer.
34. The method of claim 33, in which the presence or absence of the MHC class I restricted T cell response is determined by the method of any one of claims 30 to 32.
35. A method of causing the replication of MHC class I restricted T cells which recognize an epitope of a cancer cell or an activated T cell, said method comprising contacting a population of cells which comprises MHC class I restricted T cells with the polypeptide of any one of claims 1 to 3 or with the analogue of claim 4 under conditions in which the polypeptide or the analogue are presented to T cells in the population, or with a product of claim 26 or 27 or with a cell of claim 29.
36. A pharmaceutical composition comprising a product of claim 26 or 27, a cell of claim 28, the T cell of claim 24 or 25, or a cell which has been replicated in the method of claim 35.
37. A kit for carrying out a method of any one of claims 30 to 35 comprising a polypeptide of any one of claims 1 to 3, an analogue of claim 4, a polynucleotide of any one of claims 5 to 10, a composition of claim 17 and/or a product of claim 26 or 27.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9921242.5 | 1999-09-08 | ||
| GBGB9921242.5A GB9921242D0 (en) | 1999-09-08 | 1999-09-08 | Cancer vaccine and diagnosis |
| EP99402237.4 | 1999-09-10 | ||
| EP99402237 | 1999-09-10 | ||
| US18721500P | 2000-03-03 | 2000-03-03 | |
| US60/187,215 | 2000-03-03 | ||
| PCT/EP2000/008761 WO2001018035A2 (en) | 1999-09-08 | 2000-09-07 | Muc-1 derived peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2383737A1 true CA2383737A1 (en) | 2001-03-15 |
| CA2383737C CA2383737C (en) | 2011-01-18 |
Family
ID=27240232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2383737A Expired - Fee Related CA2383737C (en) | 1999-09-08 | 2000-09-07 | Muc-1 derived peptides |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20050142640A1 (en) |
| EP (1) | EP1210430B1 (en) |
| JP (1) | JP2003510094A (en) |
| AT (1) | ATE338121T1 (en) |
| AU (1) | AU778701B2 (en) |
| CA (1) | CA2383737C (en) |
| DE (1) | DE60030450T2 (en) |
| DK (1) | DK1210430T3 (en) |
| ES (1) | ES2270870T3 (en) |
| PT (1) | PT1210430E (en) |
| WO (1) | WO2001018035A2 (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090004212A1 (en) * | 1997-12-30 | 2009-01-01 | Franz-Georg Hanisch | Tumour vaccines for MUC1-positive carcinomas |
| JP2003533181A (en) * | 2000-02-01 | 2003-11-11 | ジ・オースティン・リサーチ・インスティテュート | Mucin-1 derived antigen and its use in immunotherapy |
| EP1531842A4 (en) | 2000-12-22 | 2007-03-07 | Dana Farber Cancer Inst Inc | Regulation of cell growth by muc1 |
| WO2002076485A2 (en) | 2001-03-27 | 2002-10-03 | Biomira, Inc. | Vaccine for modulating between t1 and t2 immune responses |
| EP2314712B1 (en) | 2001-11-07 | 2014-01-08 | Mannkind Corporation | Expression vectors encoding epitopes of antigens and methods for their design |
| EP1497649A4 (en) * | 2002-04-22 | 2006-03-22 | Dyax Corp | Antibodies specific for mucin polypeptide |
| GB0212036D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0212046D0 (en) * | 2002-05-24 | 2002-07-03 | Glaxo Group Ltd | Vaccines |
| GB0304634D0 (en) * | 2003-02-28 | 2003-04-02 | Glaxo Group Ltd | Vaccines |
| US7696306B2 (en) * | 2003-07-11 | 2010-04-13 | Board of Agents of the University of Nebraska | Compositions and methods for preventing or treating cancer |
| GB0321614D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Vaccines |
| WO2005042573A1 (en) | 2003-10-24 | 2005-05-12 | Dana-Farber Cancer Institute, Inc. | Modulation of the interaction of muc1 with muc1 ligands |
| AU2004299457B2 (en) * | 2003-12-12 | 2011-03-24 | Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services | A human cytotoxic T-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of MUC-1 |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| PT1896051E (en) | 2005-06-28 | 2015-01-13 | Oncothyreon Inc | Method of treating patients with a mucinous glycoprotein (muc-1) vaccine |
| WO2008011672A1 (en) * | 2006-07-25 | 2008-01-31 | 4G Vaccines Pty Ltd | A cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide |
| US9487574B2 (en) | 2006-09-21 | 2016-11-08 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
| US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
| WO2008097844A2 (en) | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
| WO2009108807A1 (en) * | 2008-02-26 | 2009-09-03 | The Regents Of The University Of California | Glycopeptides and methods of making and using them |
| MX2011004082A (en) | 2008-10-17 | 2011-10-14 | Dana Farber Cancer Inst Inc | Muc-1 cytoplasmic domain peptides as inhibitors of cancer. |
| US8614186B2 (en) | 2009-05-27 | 2013-12-24 | Dana-Farber Cancer Institute, Inc. | Inhibition of inflammation using antagonists of MUC1 |
| WO2011100688A1 (en) | 2010-02-12 | 2011-08-18 | Dana-Farber Cancer Institute, Inc. | Improved antagonists of muc1 |
| EP2374470A1 (en) * | 2010-04-08 | 2011-10-12 | Beta Innov | Therapeutic use of the Beta2m protein |
| US9597392B2 (en) | 2010-05-10 | 2017-03-21 | Ascend Biopharmaceuticals Pty Ltd. | Use of high molecular weight mannan for inducing and/or enhancing an immune response |
| CA2825972A1 (en) | 2011-02-24 | 2012-08-30 | Oncothyreon Inc. | Muc1 based glycolipopeptide vaccine with adjuvant |
| CN104024429B (en) | 2011-08-17 | 2019-06-04 | 全球免疫股份有限公司 | Yeast-MUC1 immunotherapeutic composition and application thereof |
| DK2800762T3 (en) * | 2012-01-03 | 2018-04-16 | Us Health | NATIVE AND AGONISTIC CTL EPITOPES OF THE MUC1 TUMOR ANTIGEN |
| US9044421B2 (en) | 2012-03-28 | 2015-06-02 | Genus Oncology, Llc | Treating MUC1-expressing cancers with combination therapies |
| TW201639868A (en) | 2015-03-09 | 2016-11-16 | Nec Corp | Peptide derived from muc1, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cells |
| EP3903811A1 (en) * | 2020-05-01 | 2021-11-03 | R.G.C.C. Holdings AG | Pharmaceutical composition and method for inducing an immune response |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281061A (en) * | 1979-07-27 | 1981-07-28 | Syva Company | Double antibody for enhanced sensitivity in immunoassay |
| ZA898777B (en) * | 1988-11-17 | 1990-12-28 | Univ Melbourne | Monoclonal antibodies |
| FR2668064B1 (en) * | 1990-10-23 | 1994-12-16 | Transgene Sa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR. |
| JPH08501280A (en) * | 1992-05-26 | 1996-02-13 | リュクスウニヴェルシテート レイデン | Peptides of human p53 protein and human p53 protein-specific cytotoxic T lymphocytes for use in a composition for inducing a human T cell response |
| IL110464A0 (en) | 1994-07-26 | 1994-10-21 | Univ Ramot | Novel proteins for the diagnosis, imaging, and therapy of human cancer |
| US6548643B1 (en) * | 1994-11-16 | 2003-04-15 | Austin Research Institute | Antigen carbohydrate compounds and their use in immunotherapy |
| US6024965A (en) | 1996-10-18 | 2000-02-15 | Erasums University Rotterdam | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
| ATE394474T1 (en) * | 1997-05-08 | 2008-05-15 | Biomira Inc | METHOD FOR OBTAINING ACTIVATED T CELLS AND ANTIGEN-PRESENTING CELLS INCUBATED WITH ANTIGEN |
| CA2322444A1 (en) * | 1998-03-05 | 1999-09-10 | Agouron Pharmaceuticals, Inc. | Non-peptide gnrh agents |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| IL125608A0 (en) * | 1998-07-30 | 1999-03-12 | Yeda Res & Dev | Tumor associated antigen peptides and use of same as anti-tumor vaccines |
| US20020052308A1 (en) * | 1999-03-12 | 2002-05-02 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
-
2000
- 2000-09-07 PT PT00965943T patent/PT1210430E/en unknown
- 2000-09-07 ES ES00965943T patent/ES2270870T3/en not_active Expired - Lifetime
- 2000-09-07 DE DE60030450T patent/DE60030450T2/en not_active Expired - Lifetime
- 2000-09-07 AU AU76515/00A patent/AU778701B2/en not_active Ceased
- 2000-09-07 EP EP00965943A patent/EP1210430B1/en not_active Expired - Lifetime
- 2000-09-07 WO PCT/EP2000/008761 patent/WO2001018035A2/en active IP Right Grant
- 2000-09-07 DK DK00965943T patent/DK1210430T3/en active
- 2000-09-07 CA CA2383737A patent/CA2383737C/en not_active Expired - Fee Related
- 2000-09-07 AT AT00965943T patent/ATE338121T1/en active
- 2000-09-07 JP JP2001527622A patent/JP2003510094A/en active Pending
-
2005
- 2005-02-11 US US11/055,119 patent/US20050142640A1/en not_active Abandoned
-
2008
- 2008-03-04 US US12/042,196 patent/US20080227082A1/en not_active Abandoned
-
2009
- 2009-10-13 US US12/578,499 patent/US7892828B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20050142640A1 (en) | 2005-06-30 |
| DE60030450T2 (en) | 2007-08-30 |
| DK1210430T3 (en) | 2006-11-20 |
| WO2001018035A9 (en) | 2002-09-06 |
| AU7651500A (en) | 2001-04-10 |
| US7892828B2 (en) | 2011-02-22 |
| DE60030450D1 (en) | 2006-10-12 |
| ES2270870T3 (en) | 2007-04-16 |
| US20080227082A1 (en) | 2008-09-18 |
| AU778701B2 (en) | 2004-12-16 |
| JP2003510094A (en) | 2003-03-18 |
| ATE338121T1 (en) | 2006-09-15 |
| EP1210430A2 (en) | 2002-06-05 |
| PT1210430E (en) | 2006-12-29 |
| EP1210430B1 (en) | 2006-08-30 |
| US20100255501A1 (en) | 2010-10-07 |
| WO2001018035A2 (en) | 2001-03-15 |
| CA2383737C (en) | 2011-01-18 |
| WO2001018035A3 (en) | 2001-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2383737A1 (en) | Muc-1 derived peptides | |
| US20200157146A1 (en) | Controlled modulation of amino acid side chain length of peptide antigens | |
| US6369211B1 (en) | MAGE-3 peptides presented by HLA class II molecules | |
| Gairin et al. | Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes | |
| JP5393144B2 (en) | HLA-A * 3303 restricted WT1 peptide and pharmaceutical composition comprising the same | |
| EP1794190B1 (en) | Immunogenic t-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes | |
| US7084247B2 (en) | Identification of self and non-self antigens implicated in autoimmune diseases | |
| US7157091B1 (en) | MAGE-A1 peptides presented by HLA class II molecules | |
| Fleischhauer et al. | Characterization of natural peptide ligands for HLA‐B* 4402 and‐B* 4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA‐B44 heavy chain | |
| PT2006294E (en) | Tumour-associated peptides that bind to mhc molecules | |
| Melief et al. | Potential immunogenicity of oncogene and tumor suppressor gene products | |
| Robbins et al. | Comparison between two peptide epitopes presented to cytotoxic T lymphocytes by HLA-A2. Evidence for discrete locations within HLA-A2. | |
| JP5189094B2 (en) | Promiscuous PAPCD4 T cell epitope | |
| JP2005512517A (en) | Inducible Hsp70-derived polypeptide and pharmaceutical composition containing this polypeptide | |
| JP4365405B2 (en) | Tumor associated peptides that bind to MHC molecules | |
| RU2011150283A (en) | TTK PEPTIDES AND VACCINES THEREOF | |
| RU2011152975A (en) | CDC45L PEPTIDES AND VACCINES INCLUDING SUCH | |
| EP0862740B1 (en) | Oncogene fusion protein peptide vaccines | |
| WO1997011669A2 (en) | Mhc-class ii restricted melanoma antigens and their use in therapeutic methods | |
| RU2011140168A (en) | VANGL1 PEPTIDES AND THEIR VACCINES CONTAINING THEM | |
| RU2011130796A (en) | C1ORF59 PEPTIDES AND THEIR VACCINES CONTAINING THEM | |
| Rees et al. | The effect of lipoylation on CD4 T-cell recognition of the 19,000 MW Mycobacterium tuberculosis antigen. | |
| RU2013115434A (en) | TTLL4 PEPTIDES AND THEIR VACCINES CONTAINING THEM | |
| US8658177B2 (en) | Promiscuous HER-2/Neu CD4 T cell epitopes | |
| ZA200202577B (en) | Modified peptides and peptidomimetics for use in immonotherapy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130909 |